Context: The very high carrier frequency of 21-hydroxylase deficiency worldwide has been postulated as indicating a survival advantage. The ‘mediators’ of such an effect remain speculative. Objective: To look for possible differences in the metabolic and atherogenic risk profile of carriers and noncarriers of CYP21A2 gene mutations at puberty in order to identify possible mediators of the presumed survival advantage for the carriers. It is anticipated that by studying atherogenic risk factors at such an early developmental stage, age-related alterations in these factors may be minimized. Methods: The study group included 45 adolescent girls diagnosed in our center with premature pubarche, 29 of whom were noncarriers and 16 carriers of CYP21A2 mutations. The two groups did not differ in chronological age, age at pubarche or menarche, pubertal stage, body mass index and waist-to-hip ratio. Biochemical and hormonal profile markers as well as markers of endothelial dysfunction were determined by appropriate methodology. Additionally, in each subject, an oral glucose tolerance test and a gonadotrophin-releasing hormone GnRH analogue stimulation test were carried out. Results: Endothelin-1 values were lower in the carriers compared to the noncarriers (p = 0.031). Higher tissue plasminogen activator and lower plasminogen activator inhibitor-1 values were found in carriers compared to noncarriers (p = 0.02 and <0.001, respectively). The ratio of the insulinogenic index/homeostasis model assessment for insulin resistance, which reflects β-cell function, was higher in carriers (p = 0.048), indicating a more favorable β-cell function in the carriers. Conclusions: Our findings that carriers of CYP21A2 gene mutations have a more favorable internal milieu with regard to the metabolic syndrome and atherogenesis support the theory that heterozygous CYP21A2 mutations provide a survival advantage. The mechanisms involved may be related to the insulin secretion-action pathway, hypothalamic-pituitary-adrenal axis responsiveness or other still unrecognized factors.

Keywords:
Premature adrenarche, CYP21, Polycystic ovary syndrome, Insulin resistance, Metabolic syndrome, adrenarche, Metabolic syndrome, pubarche, CYP21A2
1.
New MI: Steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia). Am J Med 1995;16:2S–8S.
2.
Dacou-Voutetakis C, Dracopoulou M: Non-classical congenital adrenal hyperplasia. Pediatr Endocrinol Rev 2006;3(suppl 1):195–197.
3.
White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245–291.
4.
Hochberg Z, Etzioni A: Genetic selection in nonclassical adrenal hyperplasia. J Clin Endocrinol Metab 1995;80:325–326.
5.
Witchel SF, Lee PA, Suda-Hartman M, Trucco M, Hoffman EP: Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997;82:2097–2101.
6.
Dacou-Voutetakis C, Dracopoulou M: High incidence of molecular defects of the CYP21 gene in patients with premature adrenarche. J Clin Endocrinol Metab 1999;84:1570–1574.
7.
Chrousos GP: The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 2000;24:S50–S55.
8.
Chiotis D, Krikos X, Tsiftsis G, Hatzisymeon M, Dacou-Voutetakis C: Body mass index and prevalence of obesity in subjects of Hellenic origin aged 0–18 years, living in the Athens area. Ann Clin Pediatr Univ Athen 2004;51:139–154.
9.
Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–179.
10.
Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
11.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 1997;30:S42–S47.
12.
Ahren B, Pacini G: Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004;150:97–104.
13.
Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA: β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493–500.
14.
Wedell A, Luthman H: Steroid 21-hydroxylase deficiency: two additional mutations in salt-wasting disease and rapid screening of disease-causing mutations. Hum Mol Genet 1993;2:499–504.
15.
Wilson R, Wei J-Q, Cheng K, Mercado A, New MI: Rapid deoxyribonucleic acid analysis by allele specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene. J Clin Endocrinol Metab 1995;80:1635–1640.
16.
Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE: β-Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 2002;51:2170–2178.
17.
Chandler WL, Trimble SL, Loo SC, Mornin D: Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990;76:930–937.
18.
Mertens I, Verrijken A, Michiels JJ, Van der PM, Ruige JB, Van Gaal LF: Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006;30:1308–1314.
19.
Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M: The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004;150:793–798.
20.
Andiran N, Yordam N, Kirazli S: Global fibrinolytic capacity is decreased in girls with premature adrenarche: a new pathological finding? J Pediatr Endocrinol Metab 2005;18:1373–1381.
21.
Ibanez L, Aulesa C, Potau N, Ong K, Dunger DB, de Zegher F: Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? Pediatr Res 2002;51:244–248.
22.
Silveira A: Postprandial triglycerides and blood coagulation. Exp Clin Endocrinol Diabetes 2001;109:S527–S532.
23.
Yuan J, Jia R, Bao Y: Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol 2007;31:180–188.
24.
Pandey M, Loskutoff DJ, Samad F: Molecular mechanisms of tumor necrosis factor-α-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005;19:1317–1319.
25.
Rega G, Kaun C, Weiss TW, Demyanets S, Zorn G, Kastl SP, Steiner S, Seidinger D, Kopp CW, Frey M, Roehle R, Maurer G, Huber K, Wojta J: Inflammatory cytokines interleukin-6 and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005;111:1938–1945.
26.
Vulin AI, Stanley FM: Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biochem Chem 2004;279:25172–25178.
27.
Morange PE, Aubert J, Peiretti F, Lijnen HR, Vague P, Verdier M, Négrel R, Juhan-Vague I, Alessi MC: Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999;48:890–895.
28.
Charmandari E, Merke DP, Negro PJ, Keil MF, Martinez PE, Haim A, Gold PW, Chrousos GP: Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. J Clin Endocrinol Metab 2004;89:2228–2236.
29.
Alessi MC, Juhan-Vague I: PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200–2207.
30.
Vaindirlis I, Peppa-Patrikiou M, Dracopoulou M, Manoli I, Voutetakis A, Dacou-Voutetakis C: ‘White coat hypertension’ in adolescents: increased values of urinary cortisol and endothelin. J Pediatr 2000;136:359–364.
31.
Böhm F, Pernow J: The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007;76:8–18.
32.
Schiffrin EL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001;14:83S–89S.
33.
Boesen EI, Pollock DM: Effect of chronic IL-6 infusion on acute pressor responses to vasoconstrictors in mice. Am J Physiol Heart Circ Physiol 2007;293:H1745–H1749.
34.
D’Orléans-Juste P, Plante M, Honoré JC, Carrier E, Labonté J: Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003;81:503–510.
35.
Potau N, Rique S, Eduardo I, Marcos V, Ibanez L: Molecular defects of the CYP21 gene in Spanish girls with isolated precocious pubarche. Eur J Endocrinol 2002;147:485–488.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.